Nutrition isn't a side note anymore: IISc and Tufts team up to heal through food
"It is widely recognized that food choices and nutrition play a critical role in preventing, managing, and treating diseases, and continuous research and discovery optimises care," says Christina Economos, Dean of Tufts' Gerald J and Dorothy R Friedman School of Nutrition Science and Policy.'We envision a multifaceted and flexible approach to training that equips all emerging physician-scientists and health researchers with a strong foundation in nutrition science,' she adds.THE CENTRE THAT COULD CHANGE IT ALLAt the core of this partnership is the proposed Interdisciplinary Centre for Nutrition Science and Medicine (ICNSM), which will be housed at the upcoming Tata IISc Medical School. It will combine the strengths of both institutions -- Tufts' leadership in global nutrition policy and IISc's scientific rigour and tech expertise.'This partnership can provide a platform for discovering disruptive scientific, public health, and systems-level solutions that can catalyse innovative nutritional intervention strategies and policy changes,' says Govindan Rangarajan, Director of IISc.
The centre will focus on nutrition research across disciplines -- from cancer and cardiovascular disease to immunity, gut health, ageing, and AI-powered dietary tech. It will also look at cultural factors shaping diets, including India's diverse food traditions.FOOD AS MEDICINE, NOT AFTERTHOUGHTWhat's making this alliance especially urgent is the global health reality: most diseases today aren't from viruses or bacteria, but from how we live and eat.Obesity, hypertension, diabetes, and fatty liver disease are rising sharply in India. But paradoxically, child malnutrition and micronutrient deficiencies remain widespread.According to Dr Rangarajan, 'Every third child is stunted, and more than 50% of children under 5 years of age are anaemic.' At the same time, India is the global capital of diabetes with over 100 million diabetics and 136 million pre-diabetics.This dual burden -- undernutrition and overnutrition -- demands a more sophisticated, localised approach to food as medicine. The IISc–Tufts centre will tackle just that.advertisement'We anticipate research that will impact our understanding of the role of nutrition in areas like ageing, cancer, obesity, and infectious diseases,' adds Sunil Kumar.FIXING WHAT MEDICAL EDUCATION MISSEDOne key goal of the centre is curriculum change. Nutrition competencies will be woven into the training of physicians and researchers at IISc, creating a new generation of health professionals who treat food not as an afterthought, but a first-line tool.
'Physicians may graduate without the tools or confidence to advocate for or partner with dieticians,' says Economos. 'Medical training often emphasises drugs and surgery, rather than preventing and managing illness through diet. We see this as an area of opportunity.'The centre also plans joint PhD programmes, visiting scholars, and nutrition courses co-developed by Tufts' Friedman School and IISc.GUT FEELINGS AND OLD WISDOMInterestingly, the project doesn't dismiss traditional health systems. In fact, it plans to harmonise cutting-edge gut microbiome research with Ayurvedic concepts like 'food as medicine'.advertisement'We hope to co-develop nutritional aspects unique to Indian culture,' says Dr Rangarajan. 'Traditional knowledge systems will be incorporated where applicable.'This approach respects the unique challenges of food habits and health in India -- a country where rice, roti, fermented foods, fasting, and feast all play a role in how people eat.AI, SENSORS AND PERSONALISED CAREBeyond diets and doctors, this centre also aims to bring technology into nutrition. Sensors, AI, and tele-nutrition will play a big role -- especially in low-resource settings where access to specialists is limited.'Researchers are discovering new ways to monitor a person's health and provide actionable, individualised data in real time,' says Sunil Kumar. 'This is a promising area of investigation.'There's also a plan to develop a tele-nutrition system that delivers real-time nutrition insights to primary care workers -- a game-changer for rural and underserved communities.
BEYOND THE CLINIC: ACCESS, AFFORDABILITY, AND FOOD JUSTICEOf course, no amount of tech or research will matter if healthy food isn't accessible. That's why the partnership isn't just about calories or vitamins -- it's about systems.advertisement'In areas with high levels of poverty and poor access to healthy food, obesity, diabetes and other chronic diseases are much higher than average,' says Economos. 'By tackling food access and differentiated health burdens, we can improve outcomes.'This lens is especially relevant in India, where urban poor populations often rely on ultra-processed, low-nutrition food due to cost or convenience.By focusing on food affordability, cultural eating habits, and the economics of supply chains, the centre aims to reshape healthcare at a structural level -- not just the individual.THREE THINGS THIS PROJECT DOES:Builds a new centre at IISc focused on nutrition science and integrative medicineEquips future doctors with real-world nutrition trainingUses AI and tele-nutrition to expand access in low-resource areas
At the heart of it, this collaboration is based on a simple truth: what we eat doesn't just affect how we feel -- it determines how we live. And now, finally, science and medicine are catching up.advertisementAs Economos puts it, 'Nutrition plays a critical role in the prevention, management, and treatment of both communicable and non-communicable diseases. Ongoing research and discovery are essential to optimising care.'This time, the prescription might just begin at your plate.- Ends
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Cheaper cancer care therapy earns big bucks for pharma company
India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow challenges. ImmunoACT, in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 crore. Founded by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in 2018. ImmunoACT's NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October 2023. NexCAR19 was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in India. In CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion." Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla, Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts. Globally, CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
Time of India
2 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
NDTV
3 hours ago
- NDTV
Woman Denied Boarding At Miami Airport Due To Cosmetic Procedure, Airline Responds
A woman claimed that she was denied boarding by Spirit Airlines at Miami International Airport Wednesday afternoon because of concerns over a cosmetic procedure she underwent days earlier. The Houston-based woman, named Shataria Banks, captured a video of her confrontation at the Spirit Airlines desk at the airport. "Even though y'all have my medical clearance, even though my doctor's-y'all are still restricting me to fly," Banks is heard saying in the video. While speaking to CBS News, she said she had arrived in Miami from Houston last week for a cosmetic procedure. She didn't reveal details about the procedure and preferred to keep it private. She came to the airport with documentation from her doctor clearing her to fly after several days of recovery. However, she was told that she would not be allowed to board when she tried to check in. "Well, we don't have it in writing-verbatim-from their spirit supervisor. It was just how I was treated on top of them just neglecting what my doctor said," Banks said, describing the exchange with Spirit employees. Here's what the airline said: "The safety and well-being of our Guests is our top priority. Our records show the agents followed our procedures and consulted with a designated on-call medical professional via our vendor MedLink to verify the Guest's fitness to travel," Spirit Airlines said in a statement. "The medical professional at MedLink was informed of the Guest's documentation and advised that the Guest was not fit to travel based on their condition at the time and in the interest of their safety. The Guest was ultimately issued a refund for the flight." As per the report, Banks said that she understands the need for safety; however, she called for clearer protocols. "I'm not saying that they can't deny their travelers and they're looking out for their safety, but have something in place, because everybody don't have money to waste for a new flight. I never want to fly with them, ever, ever," she said. The airline paid her the refund.
